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Abstract
The Luminex Gastrointestinal Pathogen Panel (xTAG GPP) detects in one assay the most common gastroenteritis-causing pathogens and
toxins, namely adenovirus 40/41, norovirus genogroup (NG) I/II, rotavirus A, Clostridium difﬁcile toxin A/B, Campylobacter sp., Escherichia coli
O157, Enterotoxigenic E. coli heat-labile enterotoxin/heat-stable enterotoxin, Salmonella sp., Shiga-toxin producing E. coli, Shiga-like toxin (Stx)
1/2, Shigella sp., Vibrio cholerae, Yersinia enterocolitica, Cryptosporidium sp., Entamoeba histolytica and Giardia sp. In this study, we compared the
results that were obtained by testing 393 faecal samples, collected during November and December 2011 at our laboratory, using the
xTAG GPP assay with the results of the routine diagnostic procedure. This procedure includes culture for bacteria and real-time PCR for
viruses and parasites, but only if the test was requested by the clinician. If the clinician did not request the test for an xTAG GPP-positive
target, real-time PCR assays were used to conﬁrm xTAG GPP positivity. Discrepant results were also tested with real-time PCR assays. A
total of 83 targets were detected in 76 samples using xTAG GPP. The xTAG GPP assay detected 43 additional positives compared with
the routine diagnostic procedure, of which 11 targets could not be conﬁrmed by real-time PCR. The non-conﬁrmed targets were
Campylobacter (one sample), Salmonella (four samples), Shigella (one sample) and E. histolytica (ﬁve samples). The xTAG GPP was shown to
be a convenient and sensitive assay for detection of 15 major gastrointestinal pathogens in a single molecular test, but for detection of
E. histolytica and Salmonella, a conﬁrmatory assay is indicated.
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Introduction
Infectious gastroenteritis (GE) is a major public health
problem. It causes high mortality among children in the
developing world and its costs are enormous worldwide. The
overall cost of GE in the Netherlands was estimated at
€650 million in 2009 [1]. Infectious GE can be caused by a wide
range of pathogens. For most pathogens, conventional detec-
tion methods have been replaced by rapid and sensitive
molecular assays [2–4]. The molecular assays are typically
based on real-time PCR and detect a limited number of
pathogens at a time. Based on the clinical picture, the clinician
usually requests a limited number of diagnostic tests. The
Luminex Gastrointestinal Pathogen Panel (xTAG GPP)
detects in a single assay the most common GE-causing
pathogens and toxins, namely adenovirus 40/41, norovirus
genogroup (NG) I/II, rotavirus A, Clostridium difﬁcile toxin A/B,
Campylobacter sp., Escherichia coli O157, Enterotoxigenic E. coli
(ETEC) heat-labile enterotoxin (LT)/heat-stable enterotoxin
(ST), Salmonella sp., Shiga-toxin producing E. coli (STEC),
Shiga-like toxin (Stx)1/2, Shigella sp., Vibrio cholerae, Yersinia
enterocolitica, Cryptosporidium sp., Entamoeba histolytica and
Giardia sp.
To test the performance of the xTAG GPP assay, all faecal
samples submitted to the clinical microbiology laboratory for
diagnosis of GE in November–December 2011 were tested by
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this assay. The results were compared with the routine
diagnostic results. If the routine diagnostic result of an xTAG
GPP-positive target was not available because that particular
diagnostic test was not requested by the clinician, real-time PCR
assays were used to conﬁrm xTAG GPP positivity. Other
discrepant results were also tested with real-time PCR assays.
Materials and Methods
Clinical samples
All faecal samples that were submitted in November–Decem-
ber 2011 to the Department of Medical Microbiology of the
Leiden University Medical Center (LUMC) were included.
These samples were from patients with GE complaints and on
all samples one or more routine diagnostic tests were
performed. The 393 samples were obtained from 359 patients.
From most patients one sample was received, but from 21
patients, 5 patients and one patient, respectively, two, three
and four samples were acquired. Samples that were obtained
within 48 h from the same patient were not included in the
study because similar results in consecutive samples of patients
inﬂuenced the overall ﬁndings of this study.
CE-IVD xTAG GPP assay
DNA/RNA isolation for the xTAG GPP assay was performed
on the QIAsymphony SP instrument (Qiagen, Hilden, Ger-
many). Initially, 100–150 mg of faeces was used according to
the manufacturer’s instructions, but in the adapted protocol
that was performed on the last 313 samples only 50 mg of
faeces was used. The faeces were added to 1 mL Nuclisens
easyMAG Lysis Buffer (bioMerieux, Marcy-l’Etoile, France)
and 10 lL xTAG MS2 in Precellys soil grinding SK38 2 mL
tubes (Bertin Technologies, Montigny-le-Bretonneux, France).
After vortexing, 10 min incubation at room temperature and
centrifugation, 400 lL of the supernatant was extracted on the
QIAsymphony using the QIAsymphony Virus/Bacteria minikit.
The xTAG GPP assay was performed according to the
manufacturer’s instructions. In short, a single multiplex
RT-PCR is performed on 10 lL of extracted nucleic acid.
Following the incubation of the RT-PCR products with the
bead mix and reporter, the Luminex Lx-200 reading system
sorts and reads hybridization/detection reactions. Data anal-
ysis was performed by the xTAG Data Analysis Software for
the Gastrointestinal Pathogen Panel (TDAS GPP). An internal
inhibition control (MS2) is present in the xTAG GPP assay
and ‘no call’ is obtained when the internal control signal is
below the detection threshold in conjunction with the absence
of any pathogen. Negative and positive controls were included
in all runs of the xTAG GPP assay.
Routine diagnostic GE tests at the LUMC
The routine diagnostic procedure for detection of
bacteria and their toxins is culture and VIDAS, respectively,
whereas viruses and parasites are detected by real-time
PCR.
Bacterial faeces culture. The routine procedure for bacterial
faeces culture at the LUMC is based on detection of
Campylobacter sp., Salmonella sp., Shigella sp., Aeromonas sp,
Plesiomonas shigelloides and Y. enterocolitica. For culture of
Campylobacter sp. a faecal suspension is cultured on non-
selective blood agar, using a ﬁltration technique, and on
charcoal ceforperazone desoxycholate agar (CCDA). Both
plates are incubated in a micro-aerobic atmosphere at 35°C.
For culture of Salmonella sp., Shigella sp. and P. shigelloides a
diluted faecal suspension is plated directly, or after 1 day of
selenite enrichment, on xylose lysine desoxycholate (XLD) and
SS culture medium. For culture of Y. enterocolitica and
Aeromonas sp. a faecal suspension is plated on cefsulodin
irgasan novobiocine (CIN) culture medium. For all suspected
colonies biochemical identiﬁcation was carried out.
VIDAS C. difﬁcile Toxin A and B testing. VIDAS C. difﬁcile
Toxin A and B testing (Biomerieux) was performed according
to the manufacturer’s instructions.
Multiplex real-time PCR assays. Stool samples were suspended
in 600 lL (viruses) or 200 lL (STEC and parasites) phos-
phate-buffered saline containing 2% polyvinylpolypyrolidone
(PVPP, Sigma, Zwijndrecht, The Netherlands). Viral RNA
isolation was performed with the MagNA Pure LC System
(Roche Diagnostics, Penzberg, Germany) using the Total
Nucleic Acid Kit High Performance [3]. For isolation of STEC
or parasitic DNA, the PVPP suspension was treated with
sodium dodecyl sulphate-proteinase K (Qiagen, Hilden, Ger-
many) and DNA was isolated with the MagNA Pure LC System
using the DNA Isolation Kit III (Bacteria, Fungi).
Samples of patients with suspected viral GE are routinely
tested in two multiplex real-time PCR assays detecting
adenovirus group F, astrovirus, rotavirus group A, NG I and
II, and sapovirus [3]. The assay that is used to detect STEC
Stx1 and Stx2 is adapted from Schuurman et al. [5] and the
primers and probes are depicted in Table 1. Samples of
patients with suspected parasitic GE who have been in a
tropical country or who have blood in the faeces are routinely
tested in a multiplex real-time PCR assay detecting Cryptospo-
ridium sp., E. histolytica, and Giardia sp. [2]. All other samples of
patients with suspected parasitic GE are tested in a multiplex
real-time PCR assay detecting Cryptosporidium sp., Dientamoeba
fragilis and Giardia sp. [6].
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Real-time PCR assays used for conﬁrmation of xTAG GPP
positives
The real-time PCR assays that were used to conﬁrm the
xTAG GPP-positive Campylobacter sp. [7,8], C. difﬁcile [9] and
E. histolytica [10] results have been described previously. The
salmonella and shigella real-time PCR assays that were used to
conﬁrm the xTAG GPP positives are targeted on the
tetrathionate subunit B (ttrB) and invasion plasmid antigen H
(ipaH) genes, respectively, and the primers and probes are
depicted in Table 1. For analysis of discrepancies between
xTAG GPP-positive salmonella results that could not be
conﬁrmed by culture and ttrB real-time PCR, the Shigella/
Salmonella/Campylobacter Real-TM kit (Sacace Biotechnolo-
gies, Como, Italy) was performed according to the manufac-
turer’s instructions. The xTAG GPP eluate was used for
conﬁrmatory real-time PCR assays.
Results
Results of the xTAG GPP assay
In 7.6% (30/393) of the samples, ‘no call’ was obtained as a
result by the xTAG GPP assay. After ten-fold dilution of the
eluate, 2.3% (9/393) of the samples gave ‘no call’. To reduce
inhibition, the protocol was improved by decreasing the faeces
input and preparing a batch of lysis buffer and internal control,
which resulted in ‘no call’ results for 2.6% (8/313) on initial
testing and 0.3% (1/313) on retesting with ten-fold diluted
eluate of the samples.
A total of 83 targets were detected in 76 samples using the
xTAG GPP assay (Table 2). In the majority of the positive
samples (70/76) one target was detected and in, respectively,
7% (5/76) and 1% (1/76) of the positive samples, two and three
targets were detected. Norovirus, Campylobacter and C. difﬁcile
toxins were most frequently detected (20, 15 and 14 positives,
respectively). The 76 positive samples were obtained from 67
different patients. One positive sample was obtained from 58
patients during the study period, whereas two positive samples
were obtained from nine patients.
Results of the routine diagnostic procedure compared with
the xTAG GPP results
The routine diagnostic procedure detected 95 targets in the
samples that were included in the study, of which 44 were
included in the xTAGGPP assay.Of these 44 positives, 40were
in agreement and detected by xTAG GPP assay and four were
negative. The four samples that were positive by real-time PCR,
but negative in the xTAGGPP assay, contained Cryptosporidium
sp., NG II and rotavirus (Table 3). After retesting of the
discrepant samples in the xTAG-GPP assay, three samples
remained negative and only one NGII-positive sample was
positive in the xTAG-GPP assay. However, after retesting the
xTAG GPP eluates in the diagnostic real-time PCR assays the
cryptosporidium and rotavirus could not be conﬁrmed either.
Thus, the detected pathogen loads are most likely around the
detection limit of both assays. The remaining 51 positive targets
detected in the routine diagnostic procedure were not included
in the xTAG GPP assay and therefore could not have been
detected. These targets were Dientamoeba fragilis (17 samples),
Entamoeba dispar (11 samples), enterovirus (seven samples),
sapovirus (six samples), parechovirus (ﬁve samples), the mi-
crosporidium Enterocytozoon bieneusi (two samples), astrovirus
(one sample), Schistosoma spp. (one sample) and Strongyloides
stercoralis (one sample).
Results of the xTAG GPP assay compared with the routine
diagnostic results
xTAG GPP detected 43 additional positives compared with
the routine diagnostic procedure. In most cases, the target
that was detected was not requested by the clinician (31
TABLE 1. Sequences of non-published oligonucleotides used in this study
Target Primer/probe name Sequence and label (5′–3′) Reference
Salmonella (ttrB gene) Salm_s ACCGTTACGCCATGCTTATC This study
Salm_as TTGGTTTTCAATAGTGCAACTTAC
Salm-TQ-YAK YAK-TGACAGCCGATACAACGCCGCA-BHQ1
Shigella (ipaH gene) Shig_s GAATTTACGGACTGGTTCTCC This study
Shig_as TCTCATATTTCTGCTCTTCTGC
Shig-TQ-TXR TXR-CCCAGCGGTCAGCTTCCGT-BHQ2
STEC (Stx1 gene) Stx1(c)_s TGGCATTAATACTGAATTGTCATCATC Adapted from Schuurman et al. (2007)
Stx1d_s TGGCATTAATATTAAATTGCCATCAT
Stx1(c)_as GCGTAATCCCACGSACTCTT
Stx1d_as GAGTAATCCCACGCCCACTTC
STEC (Stx1, 1c, 1d gene) Stx1(c,d)-MGB-VIC VIC-ATGAGTTTCCTTCTATG-MGBNFQ
STEC (Stx2c, 2d, 2e, 2 g gene) Stx2c,d,e,g_s CCGGAATGCAAATCAGTCGT
Stx2c,d,e,g_as CCACTRAACTCCATTAACGCC
Stx2(c,d,e,g)-MGB-FAM 6FAM-ACTCACTGGTTTCATCATA-MGBNFQ
STEC (Stx2f gene) Stx2f_s GGAACGTACAGGGATGCAGATT
Stx2f_as CGTCCTCTGAACTCCATTAAATCC
Stx2f-TQ-FAM ATATGAACCAACCAGTGAATGACGCC
YAK, Yakima Yellow; TQ, Taqman probe; BHQ, black hole quencher; TXR, Texas Red; MGBNFQ, minor groove binding non-ﬂuorescent quencher; FAM, carboxyﬂuorescein.
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positives). In 12 cases, the routine diagnostic test for the
pathogen detected by xTAG GPP was performed, but
provided a negative result. The routine diagnostic procedure
for detection of bacteria and their toxins is culture and
VIDAS, respectively, whereas viruses and parasites are
detected by real-time PCR in our laboratory. All 43 xTAG
GPP additional positive targets were tested or retested by
real-time PCR and the majority (72%, 31/43) of the additional
positives could be conﬁrmed by real-time PCR. The E. coli
O157-positive sample was not further tested because there
was no molecular assay available.
Most (5/6) additional Campylobacter positives could be con-
ﬁrmed by real-time PCR. Four of the ﬁve Campylobacter positives
contained Campylobacter jejuni and the other sample contained
Campylobacter coli. None of the additional Salmonella positives could
be conﬁrmed by real-time PCR. The xTAG GPP assay was
repeated on these samples and was positive for three samples and
gave a ‘no call’ result for one sample. The four non-conﬁrmed
xTAG GPP Salmonella-positive samples have been further
investigated by Luminex Molecular Diagnostics (Toronto, Canada)
using single-plex ampliﬁcation and cloning followed by sequence
analysis, and only in one out of four samples were Salmonella-like
sequences obtained. Therefore, only this sample was concluded to
be a true positive for Salmonella and the other three samples were
most likely false-positive results of the xTAG GPP assay. Two out
of three additional Shigella positives were positive by real-time PCR.
All additional C. difﬁcile positives (including the two samples that
were negative with the VIDAS C. difﬁcile Toxin A and B testing)
could be conﬁrmed by real-time PCR targeting the tcdB gene.
TABLE 2. Overview of samples that were positive with the
xTAG-GPP assay
Target(s)
positive with
xTAG-GPP
Routine diagnostic
test result
Real-time
PCR result
ADV ADV CT 18.5 n/a
ADV ADV CT 12.6 n/a
ADV, C. dif, Shig ADV and Shig n/t,
C. dif pos
ADV CT 15.6,
Shig neg.
Camp C. jejuni n/a
Camp C. jejuni n/a
Camp C. coli n/a
Camp Camp neg. C. jejuni CT 32.2
Camp C. jejuni n/a
Camp C. jejuni n/a
Camp C. jejuni n/a
Camp Camp neg. C. jejuni CT 39.1
Camp C. jejuni n/a
Camp Camp n/t C. coli CT 28.3
Camp Camp n/t Camp neg.
Camp Camp n/t C. jejuni CT 27.3
Camp C. coli n/a
Camp + NGII C. coli + NGII inh. NGII CT 39.2
Camp + NGII NGII CT 29.2 + camp n/t C. jejuni CT 28.9
C. dif C. dif n/t C. dif CT 26.6
C. dif C. dif n/t C. dif CT 25.3
C. dif C. dif n/t C. dif CT 27.7
C. dif C. dif n/t C. dif CT 34.7
C. dif C. dif weak pos. n/a
C. dif C. dif neg. C. dif CT 34.7
C. dif C. dif n/t C. dif CT 26.6
C. dif C. dif n/t C. dif CT 26.0
C. dif C. dif n/t C. dif CT 34.5
C. dif C. dif n/t, EV CT 22.7 C. dif CT 33.7
C. dif C. dif n/t C. dif CT 36.8
C. dif C. dif neg. C. dif CT 30.4
C. dif C. dif pos. n/a
Crypto Crypto n/t Crypto CT 34.1
Crypto Crypto CT 25.1 n/a
Crypto Crypto CT 32.1 n/a
E. coli O157 E. coli O157 n/t n/t
E. his E. his neg. E. his neg.
E. his E. his neg. E. his neg.
E. his E. his CT 27.5 n/a
E. his E. his n/t E. his neg.
E. his E. his n/t E. his neg.
E. his E. his n/t E. his neg.
Giardia Giardia CT 28.8 n/a
Giardia Giardia CT 27.2 n/a
Giardia Giardia n/t CT 28.2
Giardia Giardia n/t,
Sapo CT 37.4
CT 23.6
Giardia Giardia CT 16.2 n/a
Giardia Giardia CT 19.6 n/a
Giardia + NGI Giardia CT 25.5 + NGI CT 27.5
+ Parecho CT 34.2
n/a
Giardia + NGII Giardia CT 22.4 + NGII CT 30.2 n/a
Giardia + Shig Giardia + Shig n/t Giardia CT 22.9,
Shig CT 22.0
NGII NGII CT 16.6 n/a
NGII NGII CT 23.0 n/a
NGII NGII CT 21.1 n/a
NGII NGII CT 25.1 n/a
NGII NGII n/t NGII CT 37.3
NGII NGII n/t NGII CT 22.2
NGII NGII CT 27.9 n/a
NGII NGII CT 21.9 n/a
NGII NGII neg. + Sapo CT 27.5 NGII CT 37.9
NGII NGII CT 18.2 n/a
NGII NGII CT 28.0 n/a
NGII NGII CT 18.2 n/a
NGII NGII CT 24.8 n/a
NGII NGII CT 21.7 + Parecho CT 36.8 n/a
NGII NGII n/t NGII CT 27.4
NGII NGII CT 24.1 n/a
Rota Rota CT 28.2 n/a
Salm Salm n/t Salm neg.
Salm Salm neg. Salm neg.
Salm Salm neg. Salm neg.
Salm Salm neg. Salm neg.
Shig Shig neg. Shig CT 26.0
STEC STEC n/t Stx2 CT 28.3
STEC STEC n/t Stx1 CT 30.9,
Stx2 CT 30.2
Table 2 (Continued)
Target(s)
positive with
xTAG-GPP
Routine diagnostic
test result
Real-time
PCR result
STEC STEC n/t Stx1 CT 32.8,
Stx2 CT 32.3
STEC STEC CT 29.2 n/a
n/a, not applicable; n/t, not tested; neg., negative; pos., positive; ADV, adenovirus
40/41; C. dif, Clostridium difﬁcile toxin A/B; Camp, Campylobacter sp.; Shig, Shigella
sp.; NGI/II, norovirus genogroup I/II; EV, enterovirus; Crypto, Cryptosporidium sp.;
E. his, Entamoeba histolytica; Sapo, sapovirus; Parecho, parechovirus; Rota,
rotavirus; Salm, Salmonella sp.; STEC, Shiga-toxin producing E. coli.
TABLE 3. Targets detected by the routine diagnostic proce-
dure that were negative with the xTAG-GPP assay
Target
Initial testing Repeated testing
xTAG-GPP PCR xTAG-GPP PCR
Crypto neg. CT 38.4 neg. neg.
NGII neg. CT 28.6 neg. CT 37.3
NGII neg. CT 32.2 pos. CT 34.9
Rota neg. CT 38.6 neg. neg.
neg., negative; pos., positive; Crypto, Cryptosporidium sp.; NGII, norovirus
genogroup II; Rota, rotavirus.
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Neither the diagnostic real-time PCR nor an additional
real-time PCR on another target could conﬁrm the additional
E. histolytica-positive samples. For four out of ﬁve samples the
xTAG GPP results were negative after repeating the assay
with new eluates, but positive with old eluates. Repeated
testing with xTAG GPP of the ﬁfth sample yielded positive
results with both old and new eluates. These discrepant
samples have been further investigated by Luminex Molecular
Diagnostics using single-plex ampliﬁcation and cloning followed
by sequence analysis. Only for three of the ﬁve samples were
amplicons observed, but sequence analysis showed that the
ampliﬁed template did not originate from E. histolytica and
therefore all ﬁve samples were concluded to be false-positive
E. histolytica results.
All ﬁve additional NGII positives could be conﬁrmed by
real-time PCR. The 2 xTAG GPP NGII-positive samples that
were negative or inhibited in the initial diagnostic real-time
PCR became positive with high CT values (CT 37.9 and CT 39.2)
upon repeating the same PCR. For the other three xTAG
GPP NGII positives norovirus testing was not requested by the
clinician, but they could all be conﬁrmed by real-time PCR.
In summary, xTAG GPP resulted in 43 additional positives
compared with the routine diagnostic procedure. Of the 31
additional positives for which the target was not requested by
the clinician, 24 targets could be conﬁrmed by real-time PCR,
six targets could not be conﬁrmed in the discrepant analysis
and one target was not further analysed. The six targets that
could not be conﬁrmed were Campylobacter (one sample),
Salmonella (one sample), Shigella (one sample) and E. histolytica
(three samples). Of the 12 additional positives for which the
routine diagnostic test was performed, but yielded a negative
result, seven targets could be conﬁrmed by real-time PCR and
ﬁve targets could not be conﬁrmed in the discrepant analysis.
The ﬁve non-conﬁrmed targets were Salmonella (three sam-
ples) and E. histolytica (two samples).
Discussion
In this study, the performance of the xTAG GPP assay was
investigated.We focused on testing the added value of the assay
by comparing its results with those of routine diagnostic
procedures. We did not perform real-time PCR assays for all
targets that can be detected by the xTAG GPP assay on all
samples and therefore we cannot deﬁne the sensitivity and
speciﬁcity of the xTAGGPP assay. However, the results of the
study show that samples thatwereweakly positive in the routine
diagnostic procedurewere detected by the xTAGGPP assay as
well. Upon improvement of the protocol, there was a large
reduction of numbers of samples with inhibition. The inhibition
rates for faeces PCRdescribed in the literature vary substantially
and in general the inhibition rate of the xTAG GPP assay was
low compared with that described in the literature [3,10,11].
A major advantage of the xTAGGPP assay is that 15 targets
are tested simultaneously, independently of the request from
the clinician. For one patient the ﬁrst sample during the study
period was positive for NGII and Giardia (both by xTAG GPP
and real-time PCR). For a second sample of the same patient that
was collected 26 days after the ﬁrst sample only parasitic targets
were requested by the clinician and the sample was negative for
Giardia (both by xTAG GPP and real-time PCR) but contained
NGII (both by xTAG GPP and real-time PCR). As no further
genotyping was performed, it is not clear whether this is still the
sameNGII episode or that xTAGGPP detected a re-infection.
For a patient with GE after kidney transplantation, the clinician
had no idea about the causing agent and requested tests for
detection of viruses, bacteria and parasites. However, all
requested tests were negative and STEC as the causing agent
of GE was overlooked. xTAG GPP showed that this sample
contained Stx2 and this could be conﬁrmed by real-time PCR.
This example illustrates the additional value of the multiplex
xTAG GPP assay, which enables a generic approach to GE
testing, resulting in additional positives for which an inappro-
priate diagnostic test was requested. However, not all addi-
tionally detected targets yielded clinically relevant information.
Out of the 11 additional C. difﬁcile toxin-positive results (ten
patients), seven were detected in samples from children
<6 months old and the other four in samples from patients
older than 5 years. The clinical relevance of C. difﬁcile toxin in
young children is unclear because neonatal asymptomatic
colonization by C. difﬁcile has been described [12,13]. Therefore
samples from young children are not routinely tested for
C. difﬁcile toxins in our hospital.
Approximately half of the positive targets detected in the
routine diagnostic procedure were not included in the xTAG
GPP assay. E. dispar is routinely tested in our laboratory to
discriminate the microscopically identical E. histolytica from
E. dispar. However, it has no clinical relevance in GE and
therefore there is no need to include this target in the xTAG
GPP assay [14]. The clinical relevance in GE of the frequently
detected D. fragilis, enterovirus and parechovirus is unclear
[15,16]. The other targets that were detected in the routine
diagnostic procedure but not included in the xTAG GPP
assay are generally accepted to be GE-causing agents [15,17].
Detection of most of these targets (astrovirus, E. bieneusi,
Schistosoma spp. and S. stercoralis) is a task for a specialist
laboratory, but inclusion of sapovirus detection in the xTAG
GPP assay should be considered [18].
The amount of xTAG GPP additional positives compared
to the routine diagnostic procedure depends on which targets
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are routinely requested by the clinician and the sensitivity of
the routine diagnostic tests. In this study, the majority of the
additional positive targets (72%) were not requested by the
clinician and the result of the pathogen-wide approach. In only
28% (12/43) of the cases, was the routine diagnostic test for
the pathogen detected by xTAG GPP performed, but
provided a negative or inconclusive result. Of the 11 xTAG
GPP targets that could not be conﬁrmed, three Salmonella and
all ﬁve E. histolytica are most likely false-positive results. No
further investigation was carried out on the positive Shigella
result that was obtained in a sample that also contained
adenovirus and C. difﬁcile toxins or on the non-conﬁrmed
Campylobacter-positive sample. For this latter sample the
bacterial load was most likely around the detection limit of
the diagnostic assays, because a sample from the same patient
from 4 days before was positive for Campylobacter (both by
xTAG GPP and real-time PCR).
As the xTAG GPP assay is an endpoint PCR with
post-PCR handling, the contamination risk is increased in
comparison to real-time PCR, which does not require
post-PCR handling. Nevertheless, upon using strict segregation
of pre- and post-PCR activities, no indications of contamina-
tion when using the xTAG GPP assay were experienced.
In conclusion, the xTAG GPP assay is a convenient and
sensitive assay for detection of 15 major gastrointestinal
pathogens in a single molecular test, although for E. histolytica
and Salmonella a conﬁrmatory assay is indicated.
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